Tumor Lymphocyte IHC
NSCLC, SCLC, tumor, UC
TUMOR, EVALUABLE, SCLC, NSCLC
Representative Singleplex and Multiplex IHC images are shown in IHC analysis of paired screening and on-treatment (week 5–6) tumor biopsies, from patients receiving itacitinib or parsaclisib in combination with pembrolizumab. Because doses of parsaclisib examined in Part 1/Group B-1/B-2 (20–30 mg once daily) may also inhibit Teff function, in Part 2, a lower dose of parsaclisib (0.3 mg once daily) was evaluated in combination with pembrolizumab in PD-(L)1 treatment-naïve patients with SCLC, NSCLC, or UC. Evaluable paired biopsy samples were available for 9 patients in Part 2 (PR, 